This is a randomized, open-label, parallel design Phase I clinical trial to evaluate the safety/tolerability and pharmacokinetic of DWJ211 in healthy volunteers
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
18
Inject the Drug into submental fat and abdominal fat via subcutaneous
Seoul National University Hospital
Seoul, South Korea
Cmax
Maximum concentration of DWJ211
Time frame: 0, 5, 10, 15, 30, 45min, 1, 1.5, 2, 4, 6, 8, 12, 16, 24h
Tmax
Time of maximum concentration
Time frame: 0, 5, 10, 15, 30, 45min, 1, 1.5, 2, 4, 6, 8, 12, 16, 24h
AUCt
Area under the drug concentration-time curve
Time frame: 0, 5, 10, 15, 30, 45min, 1, 1.5, 2, 4, 6, 8, 12, 16, 24h
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.